Evidence map›Paper›PMID 23009675›Full record

ReviewGenome medicine2012

De novo mutations in neurological and psychiatric disorders: effects, diagnosis and prevention.

Julie Gauthier, Guy A Rouleau

Abstract readReview
In one paragraph

Review in Genome medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Analysis ofJournal of clinical medicine · 2020
    Article
  6. Treatable inherited rare movement disorders.Movement disorders : official journal of the Movement Disorder Society · 2018
    Review
  7. Article
  8. Article
  9. Review
  10. Lipoid congenital adrenal hyperplasia due to STAR mutations in a Caucasian patient.Endocrinology, diabetes & metabolism case reports · 2016
    Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Julie GauthierCenter of Excellence in Neuroscience of the Université de Montréal , Quebec, Canada H2L 4MI ; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Quebec, Canada H2L 4MI.
Guy A RouleauCenter of Excellence in Neuroscience of the Université de Montréal , Quebec, Canada H2L 4MI ; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Quebec, Canada H2L 4MI ; Department of Medicine, Université de Montréal, Quebec, Canada H2L 4MI.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurological and psychiatric disorders account for a considerable proportion of the global disease burden. Although there is a high heritability and a significant genetic component in these disorders, the genetic cause of most cases has yet to be identified. Advances in DNA sequencing allowing the analysis of the whole human genome in a single experiment have led to an acceleration of the discovery of the genetic factors associated with human disease. Recent studies using these platforms have highlighted the important role of de novo mutations in neurological and psychiatric disorders. These findings have opened new avenues into the understanding of genetic disease mechanisms. These discoveries, combined with the increasing ease with which we can sequence the human genome, have important implications for diagnosis, prevention and treatment. Here, we present an overview of the recent discovery of de novo mutations using key examples of neurological and psychiatric disorders. We also discuss the impact of technological developments on diagnosis and prevention.

Identifiers

PMID23009675
PMCPMC3580441

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.